Schering-Plough slashes jobs

Oh, the curse of duplication. Schering-Plough embarked on a company-wide downsizing yesterday, eliminating hundreds of jobs in nearly all departments, including finance, research, information technology, and marketing. The reason? Schering's $14 billion acquisition of Organon Biosciences, which wrapped up in November.

A company spokeswoman told Pharmalot that "a number" of jobs had been cut in the process of integrating the two companies, but didn't specify how many.

- read the item at Pharmalot

Related Articles:
Top 8 layoffs of 2007. Report
Schering-Plough: A good company to work for. Report
Organon experiences Schering's research 'religion'. Report
Schering-Plough pays $14.4B for Organon. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.